MIM
ELDN icon

MetLife Investment Management’s Eledon Pharmaceuticals ELDN Stock Holding History

MetLife Investment Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Sell
40,918
-1,187
-3% -$4.32K ﹤0.01% 2530
2026
Q1 		$130K Buy
+42,105
New +$99.2K ﹤0.01% 2424
2025
Q3 		– Sell
-36,264
Closed -$98.3K – 2864
2025
Q2 		$98.3K Buy
+36,264
New +$109K ﹤0.01% 2547

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

MetLife Investment Management's ELDN Position: Q2 2026 in Review

MetLife Investment Management reduced its Eledon Pharmaceuticals (ELDN) stake by 2.8% in Q2 2026, selling an estimated $4.32K and leaving 40,918 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #2530.

MetLife Investment Management first reported a position in ELDN in Q2 2025 and has held it in 3 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • MetLife Investment Management held 40,918 shares of Eledon Pharmaceuticals worth $161K as of Q2 2026.
  • MetLife Investment Management sold 1,187 Eledon Pharmaceuticals shares in Q2 2026, an estimated $4.32K.
  • Eledon Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2530 holding.
  • MetLife Investment Management first reported a position in Eledon Pharmaceuticals in Q2 2025 and has held it in 3 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.